BIOCOM Announces Leadership Change

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ -- The Biocom Institute announced today that Kristie Grover has resigned as Executive Director, effective February 28, to assume the Executive Director position at Chelsea's Light Foundation.

(Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO)

"Kristie has been a member of the Biocom family for over nine years and co-founded the Biocom Institute in 2008 to provide innovative training and science education programs that enhance life science literacy," said Joseph Panetta, Chairman, Biocom Institute's Board of Directors. "We are very grateful to Kristie for all she has done, and we wish her the best as she begins a new chapter in her career."

Liisa Bozinovic has been named the new Executive Director and will take the helm starting March 3. Liisa has long history with Biocom serving as the Controller and as the Treasurer for the Biocom Institute Board of Directors. From her various roles in operations, finance and outreach she brings a vast array of experience and expertise in financial management and grant administration as well as human resources and understanding of workforce needs.

"I am pleased that Liisa Bozinovic has accepted the role as Executive Director," said Panetta. "The board looks forward to working with Liisa and the Biocom Institute staff to build to ensure that the Institute remains the gold standard in life science knowledge."

About the Biocom Institute
The Biocom Institute is the gold standard in life science knowledge. As a national leader, we have built our reputation on being responsive to industry needs. Job seekers, life science professionals and the public come to the Institute to accelerate their careers through training. Organizations work with us to connect with communities, build business and inspire innovation. We encourage the bioscience workforce to be savvy in both business and science through our online BioCollaborative certificate program. For more information please visit www.biocominstitute.org.

SOURCE The Biocom Institute

 

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com
 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.